3 results about "Thromboxanes" patented technology

The application relates to an 11-dehydrothromboxane B2 detection kit and a detection method thereof, relates to the technical field of biological detection, and comprises an activation solution, an equilibrium solution, an elution solution, an elution solution, a reconstitution solution, an internal standard solution, a calibrator and a quality control product. The detection method comprises the following steps: S1, adjusting the pH of a urine sample to 2.5-3.0 by adding phosphoric acid; S2, sucking the urine sample after pH adjustment, the calibrator and the quality control product into a centrifugal tube, reacting at 37 DEG C for 2.5-3.5 hours, adding the internal standard solution, centrifuging, and taking the supernatant for solid-phase extraction treatment; S3, solid-phase extraction; and S4, calculating the concentration of 11-DH-TXB2 in the urine according to the liquid chromatogram and the peak area of 11-DH-TXB2 in the detection sample and the corresponding internal standard peak area. The application has reliable results and is convenient to calculate.

The invention relates to the technical field of medical examination and analysis, in particular to a platelet activation marker detection method which at least comprises the following steps: mixing a sample solution, a TXB2 isotope internal standard solution and a precipitator, and carrying out vortex treatment and centrifugal treatment to obtain a serum sample; a serum sample is subjected to LC-MS / MS testing, the content of thromboxane B2 in the sample is determined on the basis of a standard curve, quantitative detection of the content of TXB2 in serum is achieved by optimizing pretreatment and LC-MS / MS (liquid chromatography-tandem mass spectrometry) parameter conditions, and compared with a traditional ELISA method, the sensitivity is higher, the accuracy is higher, the result reproducibility is good, the method is more stable and reliable, and the method is suitable for large-scale popularization and application. Popularization and implementation are easy.

The present disclosure provides a method of detecting thromboxane B2 metabolites (TXB2-M) in a urine sample, including determining the amount of thromboxane B2 metabolites (TXB2-M) in the urine sample, adjusting or normalizing the amount of thromboxane B2 metabolites (TXB2-M) to creatinine (e.g., urine creatinine or creatinine level) in the urine sample (e.g., picogram (pg) of thromboxane B2 metabolites (TXB2-M) / milligram (mg) of creatinine), and adjusting or normalizing the creatinine (e.g., pg / mg) in the urine sample to renal function. The present disclosure further comprises methods of examining or determining mortality risk or hear failure risk in a subject, as well as methods of treating subjects (i) at increased risk for heart failure and / or (ii) at increased mortality risk of cardiovascular disease, heart failure, and / or stroke.